ACTA2 and steatosis: Comparable data for ACTA2, a surrogate of HSC activation and fibrogenesis, revealed a consistent therapeutic attenuation of ACTA2 expression across all dosing parameters against a background of increasing DAPI staining which likely reflected improved hepatocyte viability, reduced steatosis, and parenchymal restoration (Figure 2D,E).